Fax: (570) 882-6509
Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95)†
A trial of the Eastern Cooperative Oncology Group
Article first published online: 17 JAN 2006
Copyright © 2006 American Cancer Society
Volume 106, Issue 4, pages 830–838, 15 February 2006
How to Cite
Friedenberg, W. R., Rue, M., Blood, E. A., Dalton, W. S., Shustik, C., Larson, R. A., Sonneveld, P. and Greipp, P. R. (2006), Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95). Cancer, 106: 830–838. doi: 10.1002/cncr.21666
Presented in part at the American Society of Hematology Meeting, San Diego, CA, December 6–9,2003.
- Issue published online: 3 FEB 2006
- Article first published online: 17 JAN 2006
- Manuscript Accepted: 1 SEP 2005
- Manuscript Revised: 22 JUL 2005
- Manuscript Received: 21 APR 2005
- Eastern Cooperative Oncology Group
- Public Health Service. Grant Numbers: CA23318, CA66636, CA21115, CA73590, CA41287, CA13650
- National Cancer Institute. Grant Number: CA31946
- National Institutes of Health, and the Department of Health and Human Services
- refractory multiple myeloma;
Preliminary studies have shown valspodar (PSC-833: Novartis Pharmaceuticals, East Hanover, NJ) to be a potent inhibitor of multidrug resistance (MDR), one cause of resistance to chemotherapy. An international randomized control study (Phase III) evaluated the use of vincristine, doxorubicin, and dexamethasone (VAD) with (n = 46) and without (n = 48) valspodar in the treatment of patients with recurring or refractory multiple myeloma.
Patients with documented recurrence or refractory myeloma were stratified based on prior treatment exposure and creatinine and randomized. Because of interaction of valspodar with vincristine and doxorubicin, the doses of these drugs were reduced compared with the VAD-alone arm, and the doxorubicin was further reduced in the last 15 patients when given with valspodar based on pharmacokinetic and toxicity studies.
There were no complete or near-complete responses. There were 29% partial responses (PRs) in the VAD-alone arm and 44% with valspodar (P = 0.2). Median progression-free survival was 7 months with VAD alone and 4.9 months with valspodar (P = 0.50). Subjective response was 19% with VAD alone and 17% with valspodar (P = 1.0). Median survival with VAD alone was 18.5 months and 15.3 with the addition of valspodar (P = 0.055). Toxicity of Grade 3 or greater was higher (P < 0.0001) in the valspodar arm (89%) compared with the VAD-alone arm (58%). The reduction of doxorubicin dose reduced toxicity but not significantly (P = 0.11).
The addition of the MDR-modulating agent valspodar to VAD did not improve treatment outcome. Toxicity was increased in the valspodar-treated group compared with VAD alone. Cancer 2006. © 2006 American Cancer Society.